Genomic profiling establishes a shared clonal origin with the primary tumor (for example, by confirming a founder EGFR mutation) while also identifying secondary alterations that drive plasticity, such as the loss of RB1 and TP53 [25]. This evidence concerns the gene TP53 and neoplasm.